11 completed, 1 not yet recruiting, 1 recruiting, 1 suspended. 16 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 11, Not yet recruiting 1, Recruiting 1, Suspended 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
Follow Sleep: new trials by email Literature Review of Sleep trials Research Report on Sleep
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP) KETONE-IQ 20 grams (g), KETONE-IQ 40 grams (g) - Healthy Participants, Sleep | Phase 1 | Completed | Johns Hopkins University | 20 | 2025-12-18 | 2026-09-28 |
| Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca - Chronic Insomnia, Sleep Deprivation | Phase 1 | Not yet recruiting | Nyree Penn | 100 | 2025-11-01 | 2025-05-28 |
| Nurse-Led Elderly Sleep Intervention Otago programme, Otago programme + Cognifit, Control - Sleep, Gerontology | Phase 1 / Phase 2 | Completed | University of Castilla-La Mancha | 66 | 2025-09-01 | 2026-05-22 |
| Impact of Nutritional Supplementation on Sleep Quality Sleep Supplements, Placebo - Sleep, Sleep Quality | Phase 1 | Completed | Pharmavite LLC | 376 | 2025-05-15 | 2026-02-27 |
| Impact of Exogenous Ketones on Sleep Apnea Ketone-IQ, Placebo - Obstructive Sleep Apnea, Sleep | Phase 1 / Phase 2 | Withdrawn | Johns Hopkins University | 2025-01-29 | 2026-09-21 | |
| Impact of Exogenous Ketones on Sleep Disruption in Vulnerable Populations Ketone-IQ (1,3 Butanediol) - Obstructive Sleep Apnea, Sleep | Phase 1 | Suspended | Johns Hopkins University | 30 | 2025-01-29 | 2026-06-23 |
| Affect of Duavive on Mood & Anxiety Symptoms Duavive 0.45Mg-20Mg Tablet - Menopause, Depression, Anxiety | Phase 1 | Recruiting | St. Joseph's Healthcare Hamilton | 30 | 2024-07-03 | 2024-12-03 |
| Consciousness, Psilocybin, and Well-Being Psilocybin, Clonidine, Saline - Healthy, Psychedelic Experiences | Phase 1 | Completed | University of Wisconsin, Madison | 6 | 2023-11-07 | 2025-05-16 |
| Remote-delivered MBCT for SCAD Survivors MBCT - Acute Coronary Syndrome, Coronary Artery Disease | Phase 1 | Completed | Massachusetts General Hospital | 19 | 2021-11-04 | 2024-09-19 |
| Can Ammonium Inhalants Maintain Performance in Sleep Deprived Soldiers? Ammonia Inhalant - Sleep Deprivation, Military Activity | Phase 1 | Completed | Jan Malecek | 18 | 2020-10-01 | 2023-05-22 |
| Investigating the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep Rest-ZZZ, Active Comparator - Diphenhydramine HCl, Placebo - Sleep, Healthy | Phase 1 | Completed | LifeSeasons Inc. | 27 | 2019-09-24 | 2021-03-02 |
| A Personalized Behavioral Intervention to Improve Physical Activity, Sleep and Cognition in Sedentary Older Adults ELDERFITNESS, Control - Sleep | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 129 | 2019-07-11 | 2023-03-08 |
| Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic Dexmedetomidine, Saline Placebo - Sleep, Insomnia | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 15 | 2016-10-01 | 2019-10-02 |
| Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers PF-04457845 / matched placebo - Healthy, Sleep | Phase 1 | Completed | Pfizer | 30 | 2010-04-01 | 2018-12-04 |
| A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers PF-04457845 / matched placebo - Sleep, Healthy Volunteers | Phase 1 | Terminated | Pfizer | 18 | 2009-11-01 | 2010-07-08 |
| Bright Light: A Novel Treatment for Anxiety Litebook Bright Light Box, Litebook inactivated negation ion generator (the placebo) - Anxiety, Depression | Phase 1 | Completed | University of South Carolina | 33 | 2006-10-01 | 2021-04-28 |
Anxiety Disorders (4) · Depression (3) · Ketosis (3) · Sleep Initiation and Maintenance Disorders (3) · Sleep Apnea Syndromes (2) · Sleep Apnea, Obstructive (2) · Sleep Deprivation (2) · Acute Coronary Syndrome (1) · Alzheimer Disease (1) · Cancer Pain (1) · Chronobiology Disorders (1) · Combat Disorders (1) · Coronary Artery Disease (1) · Idiopathic Hypersomnia (1) · Motor Activity (1)
Mental Disorders (7) · Dyssomnias (6) · Nervous System Diseases (6) · Sleep Wake Disorders (6) · Sleep Disorders, Intrinsic (5) · Behavior (4) · Acid-Base Imbalance (3) · Acidosis (3) · Behavioral Symptoms (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Apnea (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Respiration Disorders (2)
N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide (2) · Sodium Chloride (2) · 1,3-butylene glycol (1) · Ammonia (1) · Clonidine (1) · Dexmedetomidine (1) · Electroencephalography (1) · Phototherapy (1) · Propofol (1) · Psilocybin (1)
Johns Hopkins University (4) · Massachusetts General Hospital (2) · Pfizer (2) · Jan Malecek (1) · LifeSeasons Inc. (1) · Nyree Penn (1) · Pharmavite LLC (1) · St. Joseph's Healthcare Hamilton (1) · University of Castilla-La Mancha (1) · University of South Carolina (1) · University of Wisconsin, Madison (1)
United States (12) · Canada (2) · Czechia (1) · Spain (1)
Jonathan Jun, MD (3) · Alison Shea, MD (1) · Charles Raison, MD (1) · Christina M Luberto, PhD (1) · David Crowley, MD (1) · Jan Malecek (1) · Junxin Li, PhD (1) · Nyree Penn, MHSc., CAA, Master of Health Science (1) · Shawn D Youngstedt (1)
PMID 21254315, PMID 41120129, PMID 41925207
P30AG064198 (1), R00NR016484 (1)